Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Oncology · Chronic Graft-Versus-Host Disease

Survivorship & Daily Management: Living with Chronic GVHD

At a Glance

Living with chronic GVHD requires shifting your focus to survivorship and symptom management. Build a multi-disciplinary care team, practice daily skin and eye care, and strictly avoid live vaccines to protect your heavily suppressed immune system from serious infections.

Living with chronic Graft-Versus-Host Disease (cGVHD) is a marathon, not a sprint. While the initial focus of your transplant was survival, the focus now shifts to survivorship—maintaining your quality of life, managing symptoms, and finding a “new normal.” Chronic GVHD can affect your physical health, your emotional well-being, and your ability to return to work or daily activities [1][2].

Building Your Multi-Disciplinary Care Team

Because cGVHD can affect almost any organ, a single doctor cannot manage it alone. You need a team of specialists who understand the unique needs of transplant survivors.

  • The Transplant Team: Your “home base” for managing the immune-suppressing medications.
  • Ophthalmologist (Eye Specialist): Essential for managing ocular cGVHD. They can provide specialized treatments like scleral lenses or serum tears to manage severe dryness [3][4].
  • Dermatologist (Skin Specialist): They monitor for skin thickening (sclerosis) and can offer specialized light therapy (phototherapy) to help soften the skin [5][6].
  • Dentist: People with oral cGVHD are at a higher risk for cavities and oral cancers [7]. Regular exams and specialized mouthwashes for dryness (xerostomia) are vital [8][9].
  • Physical/Occupational Therapist: Crucial for maintaining your range of motion if your skin or joints become stiff [10].

Managing the Daily Physical Burden

Small, daily actions can make a significant difference in how you feel:

  • Skin Care: Use thick, fragrance-free moisturizers several times a day. If you have open sores or ulcers, your team may recommend specialized gels [11].
  • Eye Care: Use preservative-free artificial tears frequently. Protect your eyes from wind and bright light with wrap-around sunglasses.
  • Oral Care: Avoid spicy or acidic foods if they cause pain. Use a soft toothbrush and fluoride treatments to protect your enamel.
  • Exercise: Gentle, consistent movement like walking or swimming helps prevent joint contractures (permanent stiffness) [10].

Navigating the Emotional Toll and Caregiver Burnout

It is completely normal to feel a sense of “health-related fatigue,” anxiety, or depression when dealing with a long-term condition [12][13].

  • Fatigue & Sleep: cGVHD-related fatigue is often linked to insomnia and mood changes. Don’t dismiss it as just “being tired”—it is a clinical symptom that your team can help manage [12].
  • Caregiver Burnout: Chronic GVHD affects the entire family. Caregivers often experience profound emotional exhaustion while managing medications, appointments, and household duties. Acknowledging this burden and seeking respite care or therapy is a necessary part of the survivorship plan.
  • Support Systems: Group-based interventions or online support communities for GVHD survivors and caregivers can provide coping skills and a sense of connection [14][15].

Understanding the Risks and Protecting Your Health

The primary risk associated with chronic GVHD is not just the disease itself, but the profound immune suppression required to treat it. Severe cGVHD and its treatments carry a risk of non-relapse mortality (NRM), often driven by infections [16][17].

Because of this, you must fiercely protect your health:

VACCINE WARNING: You must strictly avoid all live vaccines (like the MMR, oral polio, or live varicella vaccines) while heavily immunosuppressed, as they can cause life-threatening infections. Always clear any vaccine with your transplant team first.

Empowerment Through Action: While the risks are real, the tools to manage them have never been better. The presence of mild to moderate cGVHD is often associated with a lower risk of your original cancer returning (the Graft-versus-Leukemia effect) [18]. By building a proactive, communicative care team, strictly adhering to infection protocols, and advocating for your quality of life, you are laying the groundwork to not just survive post-transplant, but to live a meaningful, full life [19][17].

Common questions in this guide

Which specialists should be on my chronic GVHD care team?
Your care team should be led by your transplant team and include specialized doctors to treat affected organs. This typically includes an ophthalmologist for eye care, a dermatologist for skin issues, a dentist for oral health, and physical therapists for joint mobility.
How can I relieve the daily physical symptoms of cGVHD?
Daily management involves using thick, fragrance-free moisturizers for your skin and preservative-free artificial tears for dry eyes. You can also avoid spicy foods to protect your mouth, and practice gentle exercises like walking to prevent permanent joint stiffness.
Why do I need to avoid live vaccines with chronic GVHD?
Treatments for chronic GVHD heavily suppress your immune system to keep the disease in check. Because of this, receiving a live vaccine can cause a life-threatening infection, so you must always clear any vaccination with your transplant team first.
Is it normal to feel constantly exhausted or depressed with cGVHD?
Yes, experiencing health-related fatigue, anxiety, or depression is completely normal when dealing with a long-term condition. This profound exhaustion is a real clinical symptom often linked to insomnia and mood changes, which your healthcare team can help you manage.
Are there any benefits to having mild chronic GVHD?
Yes, having mild to moderate chronic GVHD is often associated with a lower risk of your original cancer returning. This is known as the graft-versus-leukemia effect, where the donor immune cells help fight off any remaining cancer cells in your body.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Who should be the 'quarterback' of my care team to ensure all my specialists (eye, skin, dental) are communicating?
  2. 2.Can we review my NIH Global Severity Score and discuss how it correlates with my long-term prognosis?
  3. 3.What specific exercises or physical therapy routines do you recommend to help with joint stiffness and skin tightness?
  4. 4.How can we adjust my medications to minimize fatigue and psychological side effects while still managing my GVHD?
  5. 5.Are there any specific screenings for secondary cancers, like oral or skin cancer, that I should be having more frequently because of my chronic GVHD?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    [Evaluation of differences in quality of life in patients with chronic graft-versus-host disease].

    Huang SQ, Huang RH, Quan Y, et al.

    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2024; (45(1)):54-61 doi:10.3760/cma.j.cn121090-20231008-00162.

    PMID: 38527839
  2. 2

    Impact of chronic graft-versus-host disease on quality of life and cognitive function of long-term transplant survivors after allogeneic hematopoietic stem cell transplantation with total body irradiation.

    Gruber I, Koelbl O, Herr W, et al.

    Radiation oncology (London, England) 2022; (17(1)):195 doi:10.1186/s13014-022-02161-9.

    PMID: 36447269
  3. 3

    Ocular screening for chronic graft-versus-host disease in patients with allogeneic hematopoietic stem cell transplant.

    Pearson BG, Cortez RS, Khimani KS, Gupta PK

    Canadian journal of ophthalmology. Journal canadien d'ophtalmologie 2025; (60(1)):e11-e15 doi:10.1016/j.jcjo.2024.04.005.

    PMID: 38796172
  4. 4

    Dessicating stress triggers and exacerbates experimental ocular Graft-versus-host-disease.

    Gehlsen U, Maass M, Stary D, et al.

    The ocular surface 2025; (37()):236-246 doi:10.1016/j.jtos.2025.04.008.

    PMID: 40287060
  5. 5

    Toward Better Response Assessment of Cutaneous Chronic Graft-Versus-Host Disease: A Report from the National Institutes of Health Consensus Project Task Force.

    Markova A, Lee SJ, Modi B, et al.

    Transplantation and cellular therapy 2026; (32(6)):644.e1-644.e19 doi:10.1016/j.jtct.2026.01.009.

    PMID: 41539488
  6. 6

    Effectiveness of Oral Psoralen + UV-A (PUVA) Therapy in the Treatment of Chronic Cutaneous Graft Versus Host Disease (GVHD): A Retrospective, Observational Study Analysis from a Tertiary Care Centre.

    Sadhwani M, Kulkarni V, Melinkeri S

    Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2026; (42(1)):132-137 doi:10.1007/s12288-025-01983-3.

    PMID: 41522566
  7. 7

    Multiple and Recurrent Squamous Cell Carcinoma of the Oral Cavity After Graft-Versus-Host Disease.

    Weng X, Xing Y, Cheng B

    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 2017; (75(9)):1899-1905 doi:10.1016/j.joms.2017.02.012.

    PMID: 28322198
  8. 8

    MAIT cells and their implication in human oral diseases.

    Jiang Q, Wang F, Yang JY, Zhou G

    Inflammation research : official journal of the European Histamine Research Society ... [et al.] 2022; (71(9)):1041-1054 doi:10.1007/s00011-022-01600-3.

    PMID: 35781343
  9. 9

    Topical treatment of oral chronic graft-versus-host- disease in hematopoietic stem cell transplant recipients: A systematic review.

    Haas L, Cruz-Pamplona M

    Journal of clinical and experimental dentistry 2023; (15(5)):e420-e427 doi:10.4317/jced.60138.

    PMID: 37214749
  10. 10

    Healthcare Resource Utilization and Associated Costs in Patients With Chronic Graft-Versus-Host Disease Post-Allogeneic Hematopoietic Stem Cell Transplantation in England.

    Avenoso D, Davidson JA, Larvin H, et al.

    Transplantation and cellular therapy 2024; (30(12)):1207.e1-1207.e11 doi:10.1016/j.jtct.2024.10.002.

    PMID: 39389467
  11. 11

    The Application of Umbilical Cord Blood-derived Platelet Gel for Skin Ulcers Associated With Chronic Graft-Versus-Host Disease in Pediatrics: A Randomized Trial.

    Mohseni R, Mahdavi Sharif P, Khosravi A, et al.

    Transplantation and cellular therapy 2024; (30(7)):694.e1-694.e10 doi:10.1016/j.jtct.2024.04.013.

    PMID: 38663767
  12. 12

    [Impact of the type of hematopoietic stem-cell transplant on quality of life and psychopathology].

    Janicsák H, Masszi T, Reményi P, et al.

    Ideggyogyaszati szemle 2023; (76(1-2)):25-35 doi:10.18071/isz.76.0025.

    PMID: 36892298
  13. 13

    Clinical characterization and cytokine profile of fatigue in hematologic malignancy patients with chronic graft-versus-host disease.

    Goklemez S, Saligan LN, Pirsl F, et al.

    Bone marrow transplantation 2021; (56(12)):2934-2939 doi:10.1038/s41409-021-01419-2.

    PMID: 34433916
  14. 14

    "They knew the same struggles": perceptions of a group coping skills intervention in patients with chronic graft-versus-host disease.

    Centracchio JA, Yang DG, Jagielo AD, et al.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2025; (33(2)):102 doi:10.1007/s00520-025-09153-x.

    PMID: 39814942
  15. 15

    Group Coping Intervention in Patients With Chronic Graft-Versus-Host Disease: A Pilot Randomized Clinical Trial.

    Nelson AM, Yang D, Jagielo AD, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2024; (22(1)):34-42 doi:10.6004/jnccn.2023.7080.

    PMID: 38394783
  16. 16

    Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.

    Bhatt VR, Wang T, Chen K, et al.

    Transplantation and cellular therapy 2022; (28(1)):34-42 doi:10.1016/j.jtct.2021.10.002.

    PMID: 34637965
  17. 17

    Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium.

    DeFilipp Z, Alousi AM, Pidala JA, et al.

    Blood advances 2021; (5(20)):4278-4284 doi:10.1182/bloodadvances.2021004941.

    PMID: 34521116
  18. 18

    A systematic literature review of incidence, mortality, and relapse of patients diagnosed with chronic graft versus host disease.

    Csanadi M, Agh T, Tordai A, et al.

    Expert review of hematology 2019; (12(5)):311-323 doi:10.1080/17474086.2019.1605288.

    PMID: 30955381
  19. 19

    Ocular Chronic Graft-versus-Host Disease and Its Relation to Other Organ Manifestations and Outcomes after Allogeneic Hematopoietic Cell Transplantation.

    Jeppesen H, Gjærde LK, Lindegaard J, et al.

    Transplantation and cellular therapy 2022; (28(12)):833.e1-833.e7 doi:10.1016/j.jtct.2022.08.016.

    PMID: 36002105

This page provides educational information on managing daily life with chronic GVHD. Always consult your transplant team before starting new therapies, changing your exercise routine, or receiving any vaccines.

Get notified when new evidence is published on Graft versus host disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.